IPCA LABORATORIES Financial Statement Analysis
|
||
|
The Revenues of IPCA LABORATORIES have increased by 23.50% YoY .
The Earnings Per Share (EPS) of IPCA LABORATORIES has increased by 34.82 % YoY. |
||
| REVENUES |
| OPERATING MARGIN |
| PROFIT AFTER TAX |
| EPS |
| ROCE |
IPCA LABORATORIES Last 5 Annual Financial Results
[BOM: 524494|NSE : IPCALAB]
| Consolidated | Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 |
|---|---|---|---|---|---|
| Revenues | ₹7,662 Cr | ₹6,204 Cr | ₹5,797 Cr | ₹5,395 Cr | ₹4,619 Cr |
| Expenses | ₹6,398 Cr | ₹5,301 Cr | ₹4,539 Cr | ₹3,914 Cr | ₹3,729 Cr |
| Operating Profit (Excl OI) | ₹1,264 Cr | ₹903 Cr | ₹1,258 Cr | ₹1,481 Cr | ₹890 Cr |
| Other Income | ₹184 Cr | ₹152 Cr | ₹122 Cr | ₹129 Cr | ₹87 Cr |
| Interest | ₹141 Cr | ₹48 Cr | ₹11 Cr | ₹12 Cr | ₹20 Cr |
| Depreciation | ₹357 Cr | ₹262 Cr | ₹232 Cr | ₹209 Cr | ₹211 Cr |
| Profit Before Tax | ₹843 Cr | ₹745 Cr | ₹1,136 Cr | ₹1,389 Cr | ₹739 Cr |
| Profit After Tax | ₹529 Cr | ₹492 Cr | ₹911 Cr | ₹1,149 Cr | ₹604 Cr |
| Consolidated Net Profit | ₹547 Cr | ₹471 Cr | ₹884 Cr | ₹1,140 Cr | ₹606 Cr |
| Earnings Per Share (Rs) | ₹29.08 | ₹21.57 | ₹18.58 | ₹34.85 | ₹89.87 |
| PAT Margin (%) | 8.81 | 6.87 | 7.88 | 15.63 | 21.20 |
| ROE(%) | 11.86 | 8.70 | 8.70 | 17.92 | 27.63 |
| ROCE(%) | 15.27 | 13.10 | 11.71 | 20.46 | 30.92 |
| Total Debt/Equity(x) | 0.19 | 0.22 | 0.25 | 0.14 | 0.05 |
Key Financials |
||
| Market Cap | : | ₹ 32,634.7 Cr |
| Revenue (TTM) | : | ₹ 9,155.8 Cr |
| Net Profit(TTM) | : | ₹ 823.0 Cr |
| EPS (TTM) | : | ₹ 32.4 |
| P/E (TTM) | : | 39.7 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| IPCA LABORATORIES | -2.8% | -1.9% | -24.3% |
| SUN PHARMACEUTICAL INDUSTRIES | 0.6% | 3.6% | -12.5% |
| DIVIS LABORATORIES | 1% | 9.4% | 8% |
| CIPLA | 0.9% | 1.2% | -0.2% |
| TORRENT PHARMACEUTICALS | 1.7% | 1% | 1% |
| DR REDDYS LABORATORIES | -0.5% | -4.2% | -6.3% |
| MANKIND PHARMA | 1.5% | -3.5% | -10.6% |
| ZYDUS LIFESCIENCES | -0.6% | -4.6% | -7% |
| LUPIN | -1.6% | -4.5% | -13.3% |
IPCA LABORATORIES Revenues
[BOM: 524494|NSE : IPCALAB]
| Y-o-Y | 23.50 % |
| 5 Yr CAGR | 13.49 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2025 | ₹7,662 Cr | 23.50 | |
| Mar2024 | ₹6,204 Cr | 7.03 | |
| Mar2023 | ₹5,797 Cr | 7.45 | |
| Mar2022 | ₹5,395 Cr | 16.80 | |
| Mar2021 | ₹4,619 Cr | - | |
IPCA LABORATORIES Operating Profit
[BOM: 524494|NSE : IPCALAB]
| Y-o-Y | 39.94 % |
| 5 Yr CAGR | 9.15 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2025 | ₹1,264 Cr | 39.94 | |
| Mar2024 | ₹903 Cr | -28.18 | |
| Mar2023 | ₹1,258 Cr | -15.10 | |
| Mar2022 | ₹1,481 Cr | 66.34 | |
| Mar2021 | ₹890 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 13.32 % |
| 5 Yr CAGR | -3.82 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2025 | 16.5% | 13.32 | |
| Mar2024 | 14.56% | -32.90 | |
| Mar2023 | 21.7% | -20.98 | |
| Mar2022 | 27.46% | 42.43 | |
| Mar2021 | 19.28% | - | |
IPCA LABORATORIES Profit After Tax
[BOM: 524494|NSE : IPCALAB]
| Y-o-Y | 16.13 % |
| 5 Yr CAGR | -2.53 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2025 | ₹547 Cr | 16.13 | |
| Mar2024 | ₹471 Cr | -46.69 | |
| Mar2023 | ₹884 Cr | -22.45 | |
| Mar2022 | ₹1,140 Cr | 88.02 | |
| Mar2021 | ₹606 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | 28.24 % |
| 5 Yr CAGR | -19.71 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2025 | 8.81 % | 28.24 | |
| Mar2024 | 6.87 % | -12.82 | |
| Mar2023 | 7.88 % | -49.58 | |
| Mar2022 | 15.63 % | -26.27 | |
| Mar2021 | 21.2 % | - | |
IPCA LABORATORIES Earnings Per Share (EPS)
[BOM: 524494|NSE : IPCALAB]
| Y-o-Y | 34.82 % |
| 5 Yr CAGR | -24.58 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2025 | ₹29 | 34.82 | |
| Mar2024 | ₹22 | 16.09 | |
| Mar2023 | ₹19 | -46.69 | |
| Mar2022 | ₹35 | -61.22 | |
| Mar2021 | ₹90 | - | |
IPCA LABORATORIES Return on Capital Employed (ROCE)
[BOM: 524494|NSE : IPCALAB]
| Y-o-Y | 16.56 % |
| 5 Yr CAGR | -16.17 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2025 | 15.27% | 16.56 | |
| Mar2024 | 13.1% | 11.87 | |
| Mar2023 | 11.71% | -42.77 | |
| Mar2022 | 20.46% | -33.83 | |
| Mar2021 | 30.92% | - | |
IPCA LABORATORIES Share Price vs Sensex
| Current Share Price | : | ₹1,286.4 |
| Current MarketCap | : | ₹ 32,634.7 Cr |
| Updated EOD on | : | Oct 17,2025 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| IPCA LABORATORIES | -2.8% |
-1.9% |
-24.3% |
| SENSEX | 1.8% |
1.9% |
2.4% |
IPCA LABORATORIES related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE ALLCAP | 6.4% | 8.9% | 7.5% |
| BSE MIDSMALLCAP | 4.7% | 9% | 8.4% |
| BSE LARGEMIDCAP | 4.5% | 7.2% | 8.3% |
| BSE 500 SHARIAH | 4.3% | 4.3% | 1.1% |
| BSE 200 | 1.3% | 1.3% | -0.2% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY 500 | 1.1% | 1% | -0.5% |
| NIFTY TOTAL MARKET | 1.1% | 0.8% | -0.9% |
| NIFTY LARGEMIDCAP 250 | 0.9% | 0.8% | -0.3% |
| NIFTY HEALTHCARE INDEX | 0.9% | 1.3% | -0.2% |
| NIFTY500 MULTICAP 50:25:25 | 0.8% | 0.4% | -1.5% |
You may also like the below Video Courses
FAQ about IPCA LABORATORIES Financials
How the annual revenues of IPCA LABORATORIES have changed ?
The Revenues of IPCA LABORATORIES have increased by 23.50% YoY .
How the Earnings per Share (EPS) of IPCA LABORATORIES have changed?
The Earnings Per Share (EPS) of IPCA LABORATORIES has increased by 34.82 % YoY .
Check out Intrinsic Value of Peers of IPCA LABORATORIES
Compare Stock Analytics of Peers of IPCA LABORATORIES
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
